Brought to you by 
Glaxo to apply Arecor’s formulation technology to vaccines
20 Jun 2011
Executive Summary
Arecor Ltd. (stabilization of biological drugs) is licensing its formulation technology to GlaxoSmithKline PLC, which will apply the platform to vaccines in its pipeline.
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Vaccines
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Glaxo to apply Arecor’s formulation technology to vaccines
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice